Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers
游离 DNA 浅全基因组测序的测定验证以确定晚期癌症的“肿瘤部分”
基本信息
- 批准号:10661868
- 负责人:
- 金额:$ 29.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-19 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:Advanced Malignant NeoplasmAndrogen ReceptorBiological AssayBiopsyBloodBlood CirculationBlood TestsBlood specimenBreastCell FractionClinicalCollaborationsCollectionDNADNA sequencingDetectionDevelopmentEstrogen receptor positiveGenesGoalsHemorrhageInfectionKnowledgeLibrariesMEKsMalignant NeoplasmsMalignant neoplasm of prostateManuscriptsMetastatic breast cancerMultiple MyelomaMutateMutationPainPatientsPerformancePlasmaPloidiesProcessPrognosisProto-Oncogene Proteins c-aktProtocols documentationPublicationsQuality of lifeReproducibilityResearchResearch PersonnelRiskRoleRunningSamplingSensitivity and SpecificitySpecimenTestingTherapeuticTherapeutic Clinical TrialTherapeutic TrialsTimeTissue BanksTubeTumor-DerivedValidationWorkantagonistassay developmentbasecancer typecastration resistant prostate cancercell free DNAcomputational pipelinescost effectivegenome sequencinggenomic biomarkerimprovedineffective therapiesinhibitorinnovationliquid biopsymalignant breast neoplasmminimally invasivepatient orientedpatient responsepembrolizumabprospectivesuccesssurvival outcometherapy outcometime intervaltreatment responsetriple-negative invasive breast carcinomatumortumor DNAwhole genome
项目摘要
PROJECT SUMMARY
The overarching goal of this research is to utilize a plasma-based genomic biomarker of cell-free DNA (cfDNA)
to guide therapy in metastatic breast and other cancers. In our approach, we use a cfDNA ‘ultra low pass
whole genome sequencing’ (ULP-WGS) assay with computational pipeline (ichorCNA) to determine the
amount of tumor DNA in circulation (‘tumor fraction’; TFx). Changes in TFx may serve as an early identifier for
patients responding – or failing to respond – to therapy and cfDNA ULP-WGS provides a cost-effective,
minimally-invasive approach to determine TFx. Our ULP-WGS cfDNA assay allows rapid, precise quantitation
of TFx from a single blood sample without prior knowledge of tumor mutations. While most liquid biopsy
approaches to date have focused on tracking known alterations or commonly mutated genes in cancer, our
approach is mutation agnostic and broadly applicable across advanced cancers.
This proposal developed through deep collaboration between three primary investigators working on concert
on the development and application of a cell-free DNA assay to guide prognosis and therapy in advanced
cancers. To date, we have performed the research version of this assay on over 3000 patients samples and, in
three publications to date, we demonstrate clinical utility in metastatic breast and prostate cancer as well as
multiple myeloma. We bring expertise in clinical breast cancer, sequencing assay development, and CLIA
sequencing at scale, with a strong track record of collaboration with multiple shared publications. All three PIs
are dedicated to the success of this proposal, with distinct yet complementary roles and responsibilities.
In this proposal, we will analytically validate our cfDNA ULP-WGS assay (UH2 portion) then establish clinical
validity and prospectively evaluate performance in therapeutic clinical trials (UH3 portion). In the UH2 portion,
we will determine the sensitivity and specificity of ULP-WGS using serial dilutions of patient samples, then
assess reproducibility, repeatability, and reportable range. We will then determine performance in the context
of ‘real world’ pre-analytic variability including blood collection tube type, amount of plasma, and detection
thresholds with respect to DNA input quantity. In the UH3 portion, we will establish clinical validity by
evaluating TFx in 700 clinical plasma specimens from patients with metastatic breast cancer then advance our
understanding of cfDNA by evaluating the association of TFx with patient response to therapy and survival
outcomes. Finally, we will evaluate ULP-WGS in two prospective therapeutic clinical trials of metastatic triple-
negative breast cancer, evaluating association with response to therapy.
项目摘要
这项研究的首要目标是利用基于血浆的无细胞DNA(cfDNA)基因组生物标志物
以指导转移性乳腺癌和其他癌症的治疗。在我们的方法中,我们使用cfDNA的超低通
使用计算流水线(ichorCNA)的“全基因组测序”(ULP-WGS)测定来确定
循环中肿瘤DNA的量(“肿瘤分数”; TFx)。TFx的变化可以作为早期识别符,
对治疗有反应或没有反应的患者和cfDNA ULP-WGS提供了一种成本有效的,
微创方法来确定TFX。我们的ULP-WGS cfDNA检测可实现快速、精确的定量
在没有肿瘤突变的先验知识的情况下,从单个血液样本中提取TFx。虽然大多数液体活检
迄今为止的方法都集中在跟踪癌症中已知的改变或常见的突变基因上,我们的
该方法与突变无关,广泛适用于晚期癌症。
这项提议是通过三位主要研究人员在音乐会上的深入合作而提出的。
无细胞DNA检测的开发和应用,以指导晚期癌症的预后和治疗,
癌的迄今为止,我们已经对超过3000个患者样本进行了该测定的研究版本,
到目前为止,我们已经发表了三篇文章,证明了转移性乳腺癌和前列腺癌的临床实用性,
多发性骨髓瘤我们在临床乳腺癌、测序检测开发和CLIA方面拥有专业知识
大规模测序,与多个共享出版物合作的良好记录。所有三个PI
致力于使这一建议取得成功,其作用和责任各不相同,但相辅相成。
在本提案中,我们将分析验证我们的cfDNA ULP-WGS测定法(UH 2部分),然后建立临床试验。
有效性和前瞻性评价治疗性临床试验中的性能(UH 3部分)。在UH 2部分中,
我们将使用患者样本的系列稀释液确定ULP-WGS的灵敏度和特异性,然后
评估再现性、重复性和可报告范围。然后,我们将在上下文中确定性能
“真实的世界”分析前变异性,包括采血管类型、血浆量和检测
相对于DNA输入量的阈值。在UH 3部分,我们将通过以下方式确定临床有效性:
在700例转移性乳腺癌患者的临床血浆标本中评估TFx,然后推进我们的研究。
通过评价TFX与患者对治疗的反应和生存期的相关性来了解cfDNA
结果。最后,我们将在两项转移性三重肿瘤的前瞻性治疗临床试验中评估ULP-WGS。
阴性乳腺癌,评估与治疗反应的相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Viktor Adalsteinsson其他文献
Viktor Adalsteinsson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Viktor Adalsteinsson', 18)}}的其他基金
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers
游离 DNA 浅全基因组测序的测定验证以确定晚期癌症的“肿瘤部分”
- 批准号:
10706596 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers
游离 DNA 浅全基因组测序的测定验证以确定晚期癌症的“肿瘤部分”
- 批准号:
10192682 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
Assay Validation of Cell-Free DNA Shallow Whole Genome Sequencing To Determine 'Tumor Fraction' in Advanced Cancers
游离 DNA 浅全基因组测序的测定验证以确定晚期癌症的“肿瘤部分”
- 批准号:
9976072 - 财政年份:2020
- 资助金额:
$ 29.4万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 29.4万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 29.4万 - 项目类别: